Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Random… (NCT07505290) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial for Children With Autism Spectrum Disorder
South Korea60 participantsStarted 2026-02-19
Plain-language summary
This study aims to evaluate the efficacy of the Korean version of the PEERS® for Preschoolers (PEERS®-PS-K), a parent-assisted social skills intervention for preschool-aged children with Autism Spectrum Disorder (ASD). Participants will be randomly assigned to either the intervention group, receiving the PEERS®-PS-K program, or a wait-list control group. The study focuses on improving social skills, such as making friends and interacting with peers, through structured lessons and parent coaching.
Who can participate
Age range
4 Years – 6 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children aged 4 to 6 years (at least 4 years 0 months and less than 7 years diagnosed with Autism Spectrum Disorder (ASD) through standardized diagnostic tools(K-ADOS-2 / K-ADI-R).
* Verbal Intelligence Quotient (VIQ) of 70 or higher on the Korean Wechsler Preschool and Primary Scale of Intelligence (K-WPPSI).
* Native Korean speakers with sufficient verbal fluency to communicate in full sentences appropriate for their age.
* Capable of participating in group activities and language-based interventions as determined through a screening procedure.
* Parents or legal guardians who understand the study's purpose and provide voluntary informed consent for both themselves and their child.
Exclusion Criteria:
* Parents or legal guardians who do not consent to their child's participation in the study.
* Presence of intellectual disability or other comorbid psychiatric conditions that may interfere with study participation.
* Children exhibiting clinically significant challenging behaviors that could disrupt group sessions.
* Other clinically significant neurological, medical, visual, or hearing impairments.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from Baseline in SRS-2 Total T-score at 16 weeks
Timeframe: Baseline, Post-intervention (16 weeks), and Follow-up (32 weeks)